{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 26,
  "pageCount": 29,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/26",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.585,
        "w": 0.928,
        "x": 0.036,
        "y": 0.245
      },
      "kind": "list",
      "text": "Primary endpoint met for both DURAVYU doses\nDemonstrated immediate and clinically meaningful results without a full load of aflibercept\nSignificant improvement in vision and anatomic results paired with a meaningful reduction in treatment burden\nSub-group analysis of supplement-free eyes demonstrated results are driven by treatment with DURAVYU and not by supplemental injections\nContinued favorable safety and tolerability\nEOP2 meeting scheduled with FDA in July 2025 to solidify plans for pivotal program",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea095466-591a-4bf6-982f-6f3d5da37201",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.583,
        "x": 0.036,
        "y": 0.105
      },
      "kind": "title",
      "text": "VERONA: Phase 2 Clinical Trial Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9663fc94-7d1e-4790-b878-b07a9a95ca08",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e83d0e51-f3bc-45fa-98d9-b849ec92ce00",
      "evidence": "list/bullet: Primary endpoint met for both DURAVYU doses",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}